Source: STAT News — 2026-08-12
Summary
A STAT News investigation examines Commure, the combined Commure/Athelas health-tech company valued at $7 billion, and its aggressive sales push to get AI tools that automate billing, scheduling, and administrative workflows into health systems. The reporting details a referral incentive program under which Commure offered thousands of dollars in compensation to customers and other parties who brought in new business, alongside accounts from some customers of steep financial losses after adopting the company's products.
Key Takeaways
- Commure, formed through the Commure/Athelas combination, carries a $7 billion valuation following a $70 million raise in mid-2026, and sells AI tools targeting the administrative side of health care — billing, scheduling, and back-office workflow automation.
- STAT's reporting found the company paid thousands of dollars in various forms to customers and other parties for referring new business prospects — a cash-incentive sales tactic that raises conflict-of-interest questions when the referrers are also the company's clinical customers.
- Some customers reported steep financial losses after adopting the company's billing products, with earlier reporting cited in the piece describing clinics that saw revenue drop and faced cash-flow strain severe enough to push some toward taking out loans — allegations the company disputes.
- Commure maintains its referral programs are standard industry practice and that the large majority of its customer base is satisfied — a direct rebuttal to the investigation's framing, leaving competing accounts of the same rollout.
- The story is a reminder that the business model wrapped around clinical and administrative AI — how it's sold, financed, and incentivized — can carry as much risk for health systems as the underlying technology itself.